Area of research
Infectious Diseases · Immunology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Immunotherapy and Immune Responses, and vaccines and immunoinformatics approaches.
Oncolytic virus VG161 in refractory hepatocellular carcinoma
Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern
SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity
Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine
Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape
Antigen presentation dynamics shape the antibody response to variants like SARS-CoV-2 Omicron after multiple vaccinations with the original strain
Memory B cell development elicited by mRNA booster vaccinations in the elderly
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination
Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins
Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans
Targeting histone demethylase LSD1 for treatment of deficits in autism mouse models
Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens
Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans
Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection
Evolution of antibody immunity to SARS-CoV-2
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants
Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env
Large-Scale Characterization of the Soil Microbiome in Ancient Tea Plantations Using High-Throughput 16S rRNA and Internal Transcribed Spacer Amplicon Sequencing
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Enhanced SARS-CoV-2 neutralization by dimeric IgA
A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations
A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch